Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia
NCT ID: NCT01940198
Last Updated: 2013-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
117 participants
OBSERVATIONAL
2010-04-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life Setting
NCT01236235
Atazanavir Twice Daily
NCT00357721
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
NCT00002046
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
NCT00135343
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
NCT00028301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
3\. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir experience in HIV-1 infected patients in a primary care setting through retrospective data collection.
ii. Secondary objectives
1. To illustrate long term therapeutic efficacy of atazanavir in ART naïve and experienced HIV-1 infected patients.
2. To illustrate long term tolerability to atazanavir in ART naïve and experienced HIV-1 infected patients.
3. To identify ART treatment history in ART naïve and experienced HIV-1 infected patients on ATV.
4. To identify contraindicated therapy in ART naïve and experienced HIV-1 infected patients on ATV.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have commenced ATV between 2002-2008 (Baseline)
3. Follow-up data (clinical and laboratory) available from baseline
Exclusion Criteria
2. No follow-up data (clinical and laboratory) available from baseline
3. Patient 'lost to follow-up' with \< 2 years of follow-up data (Clinical and laboratory)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Holdsworth House Medical Practice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Mark Bloch
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Bloch, Dr.
Role: PRINCIPAL_INVESTIGATOR
Holdsworth House Medical Practice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Holdsworth House Medical Practice
Sydney, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AI424-417 ST
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.